Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1958 1
1961 1
1963 1
1964 2
1965 1
1968 2
1970 6
1971 4
1972 3
1973 1
1974 2
1975 2
1976 5
1977 1
1978 8
1979 12
1980 13
1981 7
1982 5
1983 5
1984 14
1985 5
1986 7
1987 5
1988 3
1989 11
1990 7
1991 10
1992 9
1993 18
1994 8
1995 10
1996 15
1997 19
1998 16
1999 19
2000 27
2001 20
2002 30
2003 17
2004 29
2005 34
2006 51
2007 46
2008 57
2009 71
2010 69
2011 89
2012 112
2013 111
2014 144
2015 127
2016 131
2017 166
2018 180
2019 194
2020 245
2021 308
2022 313
2023 342
2024 101

Text availability

Article attribute

Article type

Publication date

Search Results

2,925 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Ajuruchukwu
Page 1
Occult Hepatitis B Virus Infection: An Update.
Saitta C, Pollicino T, Raimondo G. Saitta C, et al. Viruses. 2022 Jul 8;14(7):1504. doi: 10.3390/v14071504. Viruses. 2022. PMID: 35891484 Free PMC article. Review.
Occult hepatitis B virus (HBV) infection (OBI) refers to a condition in which replication-competent viral DNA is present in the liver (with detectable or undetectable HBV DNA in the serum) of individuals testing negative for the HBV surface antigen (HBsAg). ...Many advance …
Occult hepatitis B virus (HBV) infection (OBI) refers to a condition in which replication-competent viral DNA is present in the liver …
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
Al-Sawaf O, Zhang C, Jin HY, Robrecht S, Choi Y, Balasubramanian S, Kotak A, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Chyla B, Paulson JN, Pallasch CP, Frenzel LP, Peifer M, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K. Al-Sawaf O, et al. Nat Commun. 2023 Apr 18;14(1):2147. doi: 10.1038/s41467-023-37648-w. Nat Commun. 2023. PMID: 37072421 Free PMC article. Clinical Trial.
In this open-label parallel-group phase-3 study, 432 patients with previously untreated CLL were randomized (1:1) to receive either 1-year venetoclax-obinutuzumab (Ven-Obi, 216 patients) or chlorambucil-Obi (Clb-Obi, 216 patients) therapy (NCT02242942). ...Af …
In this open-label parallel-group phase-3 study, 432 patients with previously untreated CLL were randomized (1:1) to receive either 1-year v …
Response.
Obi ON, Alqalyoobi S. Obi ON, et al. Chest. 2022 Jan;161(1):e67-e69. doi: 10.1016/j.chest.2021.08.061. Chest. 2022. PMID: 35000726 No abstract available.
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.
Al-Sawaf O, Zhang C, Lu T, Liao MZ, Panchal A, Robrecht S, Ching T, Tandon M, Fink AM, Tausch E, Schneider C, Ritgen M, Böttcher S, Kreuzer KA, Chyla B, Miles D, Wendtner CM, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K. Al-Sawaf O, et al. J Clin Oncol. 2021 Dec 20;39(36):4049-4060. doi: 10.1200/JCO.21.01181. Epub 2021 Oct 28. J Clin Oncol. 2021. PMID: 34709929 Free PMC article. Clinical Trial.
Median MRD doubling time was longer after Ven-Obi than Clb-Obi therapy (median 80 v 69 days). At a median follow-up of 52.4 months, a sustained significant PFS improvement was observed in the Ven-Obi arm compared with Clb-Obi (median not reached v 36.4 …
Median MRD doubling time was longer after Ven-Obi than Clb-Obi therapy (median 80 v 69 days). At a median follow-up of 52.4 mo …
Work-Life Balance.
Obi GM. Obi GM. Plast Aesthet Nurs (Phila). 2023 Jan-Mar 01;43(1):3. doi: 10.1097/PSN.0000000000000477. Plast Aesthet Nurs (Phila). 2023. PMID: 36583577 No abstract available.
First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors.
Tsimberidou AM, Vo HH, Beck J, Shia CS, Hsu P, Pearce TE. Tsimberidou AM, et al. JCO Precis Oncol. 2023 Jan;7:e2200496. doi: 10.1200/PO.22.00496. JCO Precis Oncol. 2023. PMID: 36701651 Free PMC article. Clinical Trial.
PURPOSE: OBI-999 is a novel antibody-drug conjugate comprising the Globo H-targeting antibody (OBI-888) linked to the cytotoxic payload monomethyl auristatin E. ...We conducted a phase I study of OBI-999 monotherapy in patients with advanced cancer (ClinicalT …
PURPOSE: OBI-999 is a novel antibody-drug conjugate comprising the Globo H-targeting antibody (OBI-888) linked to the cytotoxi …
On-Treatment Verification Imaging.
Sethi A, Mihailidis DN. Sethi A, et al. Med Phys. 2020 Dec 31. doi: 10.1002/mp.14693. Online ahead of print. Med Phys. 2020. PMID: 33382461 Review.
The integration of on-board imaging (OBI) with linear accelerators paved the way for Image Guided Radiation Therapy (IGRT) as it is practiced today in the clinic. ...
The integration of on-board imaging (OBI) with linear accelerators paved the way for Image Guided Radiation Therapy (IGRT) as it is p …
Two decades of pegfilgrastim: what have we learned? Where do we go from here?
De Oliveira Brandao C, Lewis S, Sandschafer D, Crawford J. De Oliveira Brandao C, et al. Curr Med Res Opin. 2023 May;39(5):707-718. doi: 10.1080/03007995.2023.2196197. Epub 2023 Apr 8. Curr Med Res Opin. 2023. PMID: 36976784 Review.
A recent prospective observational study conducted in the US demonstrated that the OBI substantially improved the adherence to and compliance with clinically recommended pegfilgrastim therapy; patients receiving pegfilgrastim via the OBI experienced a lower incidenc …
A recent prospective observational study conducted in the US demonstrated that the OBI substantially improved the adherence to and co …
Occult HBV infection.
Raimondo G, Caccamo G, Filomia R, Pollicino T. Raimondo G, et al. Semin Immunopathol. 2013 Jan;35(1):39-52. doi: 10.1007/s00281-012-0327-7. Epub 2012 Jul 26. Semin Immunopathol. 2013. PMID: 22829332 Free PMC article. Review.
Finally, evidence suggests that OBI can favor the progression of liver fibrosis, in particular in HCV-infected patients. The possible contribution of OBI to the establishment of cirrhosis also implies its possible indirect role in the development of hepatocellular c …
Finally, evidence suggests that OBI can favor the progression of liver fibrosis, in particular in HCV-infected patients. The possible …
2,925 results